From determining the antagonistic potential against ERα, to elaborating the antiproliferative activity in ERα(+) BC cell lines, including the impact on the inner mechanisms of cancer development and toxicity predicted in silico, all of the designed and synthesized hits exerted notable potency, where slight differences in the activity can be understood from the structure-based point of view. The gene discussed is ERAS; the disease is breast cancer.